title: Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
abstract: BACKGROUND
  Radioimmunotherapeutics directed against CD20 have been established in several types of B-cell non-Hodgkin's lymphoma (NHL). Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) is the only approved radio - immunoconstruct for NHL in the EU. The malignant Hodgkin's and Reed-Sternberg cells in classical Hodgkin's lymphoma (cHL) express CD20 infrequently. Thus, only very limited data of cHL patients treated with anti- CD20 immunoconstructs are available. To date, none of the patients treated with 90Y ibritumomab tiuxetan demonstrated any response.
  
  
  METHODS
  We report on a 78-year-old female patient suffering from a second systemic relapse of classical nodular lymphocyte-rich HL who experienced a complete remission (CR) after treatment with 90Y ibritumomab tiuxetan lasting over a period of 6 months.
  
  
  CONCLUSIONS
  Treatment of patients with cHL with the anti-CD20 monoclonal antibody rituximab resulted in a response rate of 22%. 90Y ibritumomab tiuxetan demonstrated superiority compared with rituximab in a randomized phase III trial. HL represents a radiosensitive tumor responding to anti-CD30 or antiferritin radioimmunotherapy. Further HL patients have to be treated with 90Y ibritumomab tiuxetan to evaluate a potential benefit.
  
  
  CONCLUSIONS
  Treatment with 90Y ibritumomab tiuxetan induced a clinically relevant CR in a patient with CD20-positive cHL. Thus, we will expand treatment of relapsed CD20-positive HL with 90Y ibritumomab tiuxetan at our institution.
authors.affiliation: Department I of Internal Medicine, University of Cologne, Germany. Roland.Schnell@uni-koeln.de
authors.forename: Roland
authors.initials: R
authors.lastname: Schnell
authors.forename: Markus
authors.initials: M
authors.lastname: Dietlein
authors.forename: Klaus
authors.initials: K
authors.lastname: Schomäcker
authors.forename: Carsten
authors.initials: C
authors.lastname: Kobe
authors.forename: Peter
authors.initials: P
authors.lastname: Borchmann
authors.forename: Harald
authors.initials: H
authors.lastname: Schicha
authors.forename: Michael
authors.initials: M
authors.lastname: Hallek
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000097:blood*; D001706:Biopsy; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008279:Magnetic Resonance Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D016499:Radioimmunotherapy; D019233:Retreatment; D000069283:Rituximab; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D015021:Yttrium Radioisotopes; D000069283:Rituximab; C422802:ibritumomab tiuxetan